Results 241 to 250 of about 10,097,070 (288)

Survival and predictors of mortality among people living with HIV (PLHIV) on antiretroviral therapy in Ethiopia (2016-2023): a retrospective cohort study. [PDF]

BMJ Open
Amogne MD, Kebede A, Asfaw D, Fetensa G, Lemessa F, Zealiyas K, Belihu WB, Tamene W, Gudeta G, Wariso FB, Hailu G, Shiferaw AY, Debel L, Dechassa W, Bejiga B, Itefa K, Hailemariam BW, Habtesilase A, Yenealem D, Bekuma TT, Bulti J, Tollera G, Tadesse G.   +22 more
europepmc   +1 more source

Mortality trends and epidemiological characteristics among people living with HIV in Huangshi, China: a time-series analysis (2004-2024). [PDF]

BMC Public Health
Wang Q, Bai H, Song L, Wang C, Xie Y, Fu B, Xie J, Li L.   +7 more
europepmc   +1 more source

Cerebral toxoplasmosis: Parasitology, diagnosis, treatment, and prevention - a narrative review. [PDF]

Curr Res Parasitol Vector Borne Dis
Orish VN, Anadjoe SA, Orish JC, Adzah D, Ablordey K, Adongo DW.   +5 more
europepmc   +1 more source

Disseminated Cryptococcosis under Fingolimod Therapy

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Sven C. Engler, Morna F. Schmidt, Ana Ortins‐Pina, David Kluwig, Amir S. Yazdi   +4 more
wiley   +1 more source

Experimental Results on Chloroquine and AIDS-Related Opportunistic Infections

JAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
Apart from its antiretroviral effects, chloroquine (CQ) has other properties that may be of interest in setting of HIV infection. First, it is an anti-inflammatory drug and, second, it may help to prevent several AIDS-related opportunistic infections.
Boelaert JR, Appelberg R, Gomes MS, BLASI, Elisabetta, Mazzolla R, Grosset J, Lounis N, Soteriadou K, Thiakaki M, Taramelli D, Tognazioli C.   +10 more
openaire   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Systemic Antifungal Agents Against AIDS-Related Opportunistic Infections: Current Status and Emerging Drugs in Development

Current Medicinal Chemistry, 1999
No effective drug was available for the treatment of systemic fungal infections until the discovery of Amphotericin 8 in 1953. Since then flucytosine, azoles and later the triazoles, have now become available. The current interest in the development of new antifungal agents can partially be explained by the dramatic rise in the number of AIDS cases ...
Seth Y Ablordeppey
exaly   +3 more sources

AIDS related opportunistic infections, going but not gone

Archives of Pharmacal Research, 2002
It is now more than two decades since the AIDS epidemic began with a cluster of Pneumocystis carinii pneumonia (PCP) in a community of homosexual men. Since then, many other infections have been characterized as opportunistic infections secondary to HIV infection. These include, but are not limited to, infections with Toxoplasma gondii, Cytomegalovirus
Rafik, Samuel, Robert L, Bettiker, Byungse, Suh   +2 more
openaire   +2 more sources

Recent Advances in the Management of AIDS-related Opportunistic Infections

Annals of Internal Medicine, 1994
• Secondary infections remain the leading cause of death in patients with the acquired immunodeficiency syndrome (AIDS). Dealing with the rapidly evolving spectrum of infectious problems seen in patients with AIDS requires knowledge of current therapeutic and prophylactic strategies.
H. Clifford Lane, Barbara E. Laughon, Judith Falloon, Joseph A. Kovacs, Richard T. Davey, Michael A. Polis, Henry Masur   +6 more
openaire   +1 more source